Introduction to the Urogen Class Action Lawsuit
The UroGen class action lawsuit seeks to represent purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”). Captioned Cockrell v. UroGen Pharma Ltd., 25-cv-06088 (D.N.J.), the UroGen class action lawsuit charges UroGen and certain of UroGen’s top current and former executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the UroGen class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at tmiles@timmileslaw.com.
Lead plaintiff motions for the UroGen class action lawsuit must be filed with the court no later than July 28, 2025.
In this guide, we provide a timeline of events for the entire duration of a typical securities class action lawsuit like the UroGen class action lawsuit, with approximately how long each step takes so you will have a better understanding of the timing of events in the UroGen class action lawsuit.
Lead Plaintiff Appointment in the UroGen Class Action Lawsuit: Approximately Four Months After Initial Complaint Filed
When a securities class action is filed such as the UroGen class action lawsuit, the person who files the first complaint is required to publish a notice announcing the filing. Anyone who wants to be lead plaintiff on behalf of the class in the UroGen class action lawsuit must thereafter file a motion to be appointed as lead plaintiff(s) no later than 60 days after the notice was published.
At the end of the sixty days, the court can rule on the lead plaintiff’s motion just on the pleading filed with the court, or the judge may set a hearing on the motion for 30–45 days after the sixty-day expiration. If a hearing is held, the judge will issue an order afterwards appointing a lead plaintiff which could be a couple weeks to a couple months.
Regardless, the PSLRA states that not later than 90 days after the initial filing and notice the court must consider the lead plaintiff’s motions and must consolidate all the related cases filed before issuing an order on the lead plaintiff. Thus, from the initial filing until a lead plaintiff is appointed, about four months have passed.
Filing of a Consolidated Complaint: Approximately Six Months After Initial Filing
After the appointment of lead plaintiff, the court will enter a scheduling order which will include a time, usually about 60 days, for the lead plaintiff to file a consolidated complaint consolidating the allegations all complaints along with any new additional allegations.
The Defendants Motion to Dismiss: Decided Nearly a Year After the Initial Complaint Was Filed
In the same scheduling order, the court will also set a time for the defendants to file a motion to dismiss and schedule a briefing and possibly a hearing on the motion once the briefing is completed. The defendants may have 45 to 60 days to file the motion to dismiss and then the briefing schedule is typically around 60 days, and the court will then enter an order either granting or denying the motion to dismiss.
Thus, by the time defendants’ motion to dismiss is decided nearly a year has passed since the filing of the original complaint in the UroGen class action lawsuit and could be possibly longer given the court’s schedule.
Completion Of Discovery: Two-and-a-Half-Years After Initial Filing
If the defendant’s motion to dismiss is denied, the parties will move into the discovery phase including the exchange of documents, request for admissions, interrogatories, depositions, and third-party subpoenas, among others.
The discovery phase usually takes about a year, though it can be less or more depending on the size of the case and its complexity.
Thus, by the time discovery is completed approximately two-and-a-half years have passed since the initial filing, which is approximately how long it takes a securities class action to resolve.
Settlement Negotiation and Mediation
By now two-and-a-half to three years have passed since the initial filing of the lawsuit. However, it is at this point that nearly all securities class actions result in a settlement, but that process takes time also. Once the parties have reached an agreement, it will have to be preliminarily approved by the court with notice to shareholders with the right to object, obtain final approval of the settlement, and then the claims process begins.
Usually, a third-party administrator is hired to administer the common fund. If the parties have complied with all the steps for approval, the judge will approve the distribution of the settlement fund by the claim’s administrator. You will receive a court-appointed notice and have to send in a claim form confirming your purchases and sales. This process alone can take up to a year and therefore it may be four years until the case is finally resolved.
Frequently Asked Questions About the UroGen Class Action Lawsuit
Q1. What is the UroGen class action lawsuit about? The lawsuit alleges that UroGen Pharma Ltd. violated federal securities laws by making false and misleading statements about its communications with the FDA regarding UGN-102, a bladder cancer treatment. Investors who purchased securities between July 27, 2023, and May 15, 2025, may be eligible to participate.
Q2. How did UroGen’s stock price react to the FDA and ODAC announcements? UroGen’s stock price experienced two significant drops. It fell 26% on May 16, 2025, after the FDA’s briefing document release, and then crashed another 45% on May 21, 2025, following the negative ODAC vote. In total, the company lost approximately 58% of its market value within five trading days.
Q3. What are the main allegations against UroGen in this lawsuit? The lawsuit claims that UroGen misled investors about FDA feedback on the UGN-102 clinical trial design. Despite FDA recommendations for a randomized controlled trial, UroGen proceeded with a single-arm study, potentially misrepresenting the likelihood of regulatory approval based on this trial structure.
Q5. What is the role of a lead plaintiff in a securities class action lawsuit? The lead plaintiff serves as the representative for all class members throughout the lawsuit. They are responsible for selecting legal counsel and making key decisions regarding the litigation. Usually, the court selects the investor with the largest financial interest who is also representative of the class to serve as lead plaintiff.
Contact Timothy L. Miles Today About a UroGen Class Action Lawsuit
If you suffered losses in UroGen stock, call us today for a free case evaluation about a UroGen Class Action Lawsuit. 855-846-6529 or tmiles@timmileslaw.com (24/7/365).
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: tmiles@timmileslaw.com
Website: www.classactionlawyertn.com
